New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants

• Main Authors: K. B. Mirzaev (Author), D. V. Ivashchenko (Author), I. V. Volodin (Author), E. A. Grishina (Author), K. A. Akmalova (Author), A. A. Kachanova (Author), A. I. Skripka (Author), R. M. Minnigulov (Author), T. E. Morozova (Author), O. A. Baturina (Author), A. N. Levanov (Author), T. V. Shelekhova (Author), A. I. Kalinkin (Author), D. A. Napalkov (Author), A. A. Sokolova (Author), D. A. Andreev (Author), I. N. Sychev (Author), P. O. Bochkov (Author), D. A. Sychev (Author)
• Format: Book
• Published: Столичная издательская компания, 2020-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29 patients (17 patients received dabigatran and 12...